Alzamend Neuro regains Nasdaq bid price compliance; MVLS deficiency still pending

Alzamend Neuro, Inc.

Nasdaq notified Alzamend on July 30, 2024 that bid price compliance is regained after 10 consecutive days above $1.00.
Minimum Bid Price Requirement was met on July 29, 2024; matter is now closed.
MVLS deficiency remains: Alzamend must demonstrate compliance with $2.5M stockholder equity by September 23, 2024.
Company appealed delisting for MVLS; hearing panel granted extension to Sept 23, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.